Chikungunya Vaccine Market Size was valued at USD 0.27 Billion in 2023. The Chikungunya Vaccine industry is projected to grow from USD 0.30 Billion in 2024 to USD 0.65 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.04% during the forecast period (2024 - 2032). Growing
incidence, rising chikungunya fever incidence and expanding government activities for chikungunya prevention and control. These are just a few of the market drivers that are driving the Chikungunya Vaccine market.
Chikungunya Vaccine Market Trends
- The growing prevalence of emerging and re-emerging infectious diseases will boost the Chikungunya Vaccine market growth
The Chikungunya virus (CHIKV), which causes the illness, is spread to people by infected mosquitoes. The mosquito species most frequently implicated in the chikungunya transmission cycle are Aedes albopictus and Aedes aegypti. The European Institute for Disease Prevention and Control announced that as of August 2022, there were 229,029 cases of chikungunya registered worldwide, along with 41 fatalities.
With people coming into closer contact with wild animals, traveling much more frequently and far greater distances than in the past and living in more densely populated areas, the potential for emerging infectious diseases to spread rapidly and cause epidemics is a major concern. There is also the potential for diseases to emerge due to the deliberate introduction into animal, human, or plant populations for terrorist purposes. There are about 40 infectious diseases that have been discovered, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently, COVID-19. Experts have warned future pandemics and epidemics to be even more lethal than COVID-19. The rising prevalence of these infectious diseases will ensure a continued and growing demand for vaccines in the coming years. Thus, factors like the emergence of new diseases will ensure better R&D funding initiatives, a strong pipeline, and new vaccine opportunities for large population segments and drive the Chikungunya Vaccine market growth.
For instance, the worldwide biopharmaceutical business of Takeda Pharmaceutical Company Ltd (Takeda) is patient-focused, values-based, and R&D-driven. It is among the biggest pharmaceutical firms in Asia. The company's primary therapeutic areas of interest are oncology, gastrointestinal, the central nervous system, uncommon disorders, and vaccines. It provides more people worldwide with transforming treatment and extremely creative medications. It is in almost 80 countries and holds the top spots in the U.S. and Japan. A vaccine product is the chikungunya vaccine (TAK-507). Therefore, recent developments related to vaccines have enhanced the Chikungunya Vaccine market CAGR globally.
The competitive pipeline, which includes items from established and up-and-coming businesses, is another significant element fueling market expansion. These firms are trying to get the regulatory agencies' permission for their items since the market is so diverse and large. Continuous R&D and a focus on releasing fresh goods are the key challenges many businesses encounter. Of the top 10 players, businesses like Inovio Pharmaceuticals, Novavax, and Bavarian Nordic are anticipated to have chances for their product pipelines shortly. Potential pipeline candidates anticipated to contribute favorably to the Chikungunya Vaccine market revenue include Pfizer, GSK, Sanofi, and Merck.
Chikungunya Vaccine Market Segment Insights
Chikungunya Vaccine Product Technology Insights
Based on Product Technology, the Chikungunya Vaccine market segmentation includes Live-Attenuated Virus Vaccines, Inactivated Viral Vaccines, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates and Others. The Live-Attenuated Virus Vaccines segment held the majority share in 2022, contributing to around ~65-67% of the Chikungunya Vaccine market revenue. For the manufacture of vaccinations, live attenuation technology is most frequently utilized. The market for live attenuated vaccines is driven by this reason globally. The characteristics of live attenuated vaccines, such as oral administration, cheap manufacturing costs, pathogen prevention, durability, and high efficacy, drive the market. One of the top 10 killers in the world is tuberculosis. One of the key reasons propelling the market for live attenuated vaccines is the rise in the number of individuals affected by infectious illnesses worldwide.
Chikungunya Vaccine Age Group Insights
The Chikungunya Vaccine market segmentation, based on age group, includes Pediatric, Adult and Geriatric. The Pediatric segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Regarding value, pediatric injections have the largest market share for vaccinations. The prospective magnitude of these is primarily influenced by two variables: an expanding birth cohort and rising pediatric immunization doses. Hence, the rise in cases of Chikungunya positively impacts the Chikungunya Vaccine market growth.
Figure 1: Chikungunya Vaccine Market, by Age Group, 2023 & 2032 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Chikungunya Vaccine Distribution Channel Insights
Distribution Channels have bifurcated the Chikungunya Vaccine market data into Hospital Pharmacies, Retail Pharmacies and Others. The Hospital Pharmacies segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Since that vaccines are a shorter-duration operation frequently carried out at smaller facilities, hospital pharmacies are predicted to have a leading revenue share. Also, the growing demand for close vaccine access will likely drive this market's development. Government agencies monitor hospitals and retail pharmacies worldwide to ensure that the demand is satisfied and that the shops have enough volume stock. Hence, rising advances and developments for Chikungunya vaccines positively impact market growth.
Chikungunya Vaccine Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Chikungunya Vaccine market accounted for USD 0.11 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to various variables like vaccination awareness, strong manufacturers, and solid government policy surrounding health welfare, the market in North America is predicted to develop gradually and hold the dominating market position. It also emphasizes the implementation of vaccination throughout the nations of North America with appropriate financial policies.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CHIKUNGUNYA VACCINE MARKET SHARE BY REGION 2022 (%) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The value of the Asia Pacific Chikungunya Vaccine market is anticipated to expand dramatically. The Asia Pacific region's diverse economic development levels lead to various vaccination strategies. Because of the growing populations of China and India, Japan has the largest market share in the Asia Pacific region. The main cause of the increased demand for injections is this aspect. Moreover, the China Chikungunya Vaccine market held the largest market share, and the India Chikungunya Vaccine market was the fastest-growing market in the Asia-Pacific region.
The Europe Chikungunya Vaccine market is anticipated to increase steadily due to the rising need for immunization to address chronic illnesses that especially call for vaccination. The government's introduction of vaccine implementation initiatives is also anticipated to stimulate market expansion. Further, the Germany Chikungunya Vaccine market held the largest market share, and the U.K. Chikungunya Vaccine market was the fastest-growing market in the European region.
Chikungunya Vaccine Key Market Players & Competitive Insights
Leading major market players companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Chikungunya Vaccine. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming more and more competitive, Chikungunya Vaccine industry competitors must provide affordable products.
Manufacturing locally to cut operational costs is one of the main business methods producers use in the Chikungunya Vaccine industry to benefit customers and increase the market sector. The Chikungunya Vaccine industry has recently given medicine some of the most important advantages. The Chikungunya Vaccine market major player such as Takeda Pharmaceutical Company Limited (Japan), Valneva SE (France), Moderna Inc (China), Emergent BioSolutions Inc (U.S.), Bharat Biotech International Limited (India), Thermis Bioscience GmbH (Austria), Auro Vaccine LLC (U.S.)Company.
With its headquarters in Saint-Herblain, France, Valneva SE is a French biotech firm that creates and sells vaccines for infectious illnesses. Reports that it has finished rolling submission of the Biologics License Application (BLA) for its single-shot chikungunya vaccine candidate, VLA1553, to the U.S. Food and Drug Administration (FDA) in December 2022. For anyone over the age of 18, Valneva is requesting clearance for its experimental chikungunya vaccine.
Merck Group, which was established in Germany in 1668 and of which it was once the American arm, Merck & Co., Inc., is an American pharmaceutical corporation with its headquarters in Rahway, New Jersey. Outside of the United States and Canada, the corporation trades as Merck Sharp & Dohme or MSD. Following a Phase II status report, Merck's chikungunya fever vaccine study shows an 11-point increase in its likelihood of moving on to the next stage.
Key Companies in the Chikungunya Vaccine market include
-
Takeda Pharmaceutical Company Limited (Japan)
-
Valneva SE (France)
-
Moderna Inc (China)
-
Emergent BioSolutions Inc (U.S.)
-
Bharat Biotech International Limited (India)
-
Themis Bioscience GmbH (Austria)
-
Auro Vaccine LLC (U.S.)
Chikungunya Vaccine Market Segmentation
Chikungunya Vaccine Product Technology Outlook
Chikungunya Vaccine Age Group Outlook
-
Pediatric
-
Adult
-
Geriatric
Chikungunya Vaccine Distribution ChannelOutlook
-
Hospital Pharmacies
-
Retail Pharmacies
-
Others
Chikungunya Vaccine Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
